Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck expands desmoteplase agreement

Lundbeck expands desmoteplase agreement

24th December 2007

Lundbeck has announced an expansion of its licensing agreement with Paion for desmoteplase, a genetically engineered form of a clot-dissolving protein found in the saliva of Desmodus rotundus vampire bats.

The firms have also announced the initiation of a new phase III clinical trial of the drug in patients with acute ischaemic stroke.

Under the revised agreement, Paion will receive an initial sum of eight million euro (5.8 million pounds), with the firm eligible to receive a total of 71 million euros in further milestone payments upon the attainment of specified development and commercialisation landmarks.

Anders Gersel Pedersen, senior vice-president and head of development at Lundbeck, said: “Desmoteplase has the potential to treat patients with acute ischaemic stroke up to nine hours after onset of symptoms.

“No treatment is available today that allows patients to reach hospital and be diagnosed within this extended time window.”

He added that the re-analysis of the recent Dias-2 study shows that patients with a detectable blood clot can benefit from treatment with the compound, while the firm is pleased to report an extension to its development agreement for the drug with Paion.

In October 2007, Paion initially reported that desmoteplase had not met the primary efficacy endpoints of a phase III study due to a lack of improvement compared to the placebo arm, though the firm reported “probable reasons for the unexpectedly good outcome” in these patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.